12.12.2024 00:59:05 CET | Thor Medical ASA | Major shareholding notifications

Oslo, Norway, 11 December 2024: Reference is made to the stock exchange
announcements by Thor Medical ASA (the "Company") on 11 December 2024 regarding
a private placement of new shares to be issued by the Company (the "Private
Placement").

Scatec Innovation AS has agreed to lend existing and unencumbered shares in the
Company, already being traded on Euronext Oslo Børs, to the manager for the
Private Placement. Borrowed shares will be used for settlement towards investors
having been allocated shares in the Private Placement and redelivered to Scatec
Innovation AS upon registration of the share capital increase pertaining to the
Private Placement.

Prior to the completion of the Private Placement, Scatec Innovation AS held
64,417,932 shares in the Company, representing approx. 27.43% of the issued
share capital and votes. Scatec Innovation AS has lent a total of 45,632,920
existing shares which will be delivered to the investors in the Private
Placement other than Scatec Innovation AS. During the term of the loan, and
prior to the redelivery, Scatec Innovation AS' shareholding in the Company will
be reduced to 18,785,012, equivalent to approx. 6.70% of the issued share
capital and votes. Consequently, Scatec Innovation AS has fallen below the 25,
20, 15 and 10% threshold pursuant to section 4-2 (1) and (3) of the Norwegian
Securities Trading Act.

The board of directors of the Company has resolved to issue 45,632,920 offer
shares in the Private Placement pursuant to the authorisation granted by the
Company's annual general meeting held on 11 April 2024, that will be subscribed
by the manager and, once issued, delivered to Scatec Innovation AS as for
redelivery of shares borrowed in relation to settlement of tranche 1 of the
Private Placement.

 

This information is subject to disclosure requirements pursuant to the EU Market
Abuse Regulation article 19 (3) and the Norwegian Securities Trading Act section
and 5-12.

 

Contacts

Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440, 
brede.ellingseter@thormedical.com

 

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

To learn more, visit www.thormedical.no - http://www.thormedical.no - 
https://www.thormedical.no.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18356878/5410/Download%20announce
ment%20as%20PDF.pdf

20241211 - Primary insider notification - share lending.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18356878/5409/20241211%20-%20Prim
ary%20insider%20notification%20-%20share%20lending.pdf